PEMBROLIZUMAB AND ATEZOLIZUMAB AS POSSIBLE EQUIVALENT FIRST-LINE THERAPEUTIC ALTERNATIVES IN PD-L1-EXPRESSING TRIPLE-NEGATIVE BREAST CANCER

M.D RIVAS RODRÍGUEZ, A.GIL GARCÍA, A. ROJAS ALBARRÁN, M. GRAGERA GÓMEZ, H. VÁZQUEZ VELÁZQUEZ, J.F RANGEL MAYORAL
University Hospital Complex of Badajoz, Hospital Pharmacy, Badajoz, Spain
Marilolirr.2612@gmail.com

BACKGROUND

Recent studies have established the influence of the immune system on disease progression in triple negative breast cancer (TNBC) patients.

OBJECTIVE

To determine if pembrolizumab and atezolizumab can be considered equivalent first-line therapeutic alternatives (ATE) by using a common comparator, for patients with locally recurrent unresectable or metastatic unresectable TNBC in adults whose tumors express PD-L1 and who have not received prior chemotherapy



MATERIALS AND METHODS

Bibliographic search → Phase III randomised clinical trials of first-line treatments for TNBC.

- The indirect comparison was performed with the **Bucher method**.
- The variable selected to determine clinical equivalence was **progression-free survival (PFS).**
- The maximum acceptable difference as a clinical non-inferiority standard Delta (D), and its inverse were set at 0.65 and 1.54, respectively. They were established by **ESMO-Magnitude of Clinical Benefit Scale**.



RESULTS

PEMBROLIZUMAB
CPS≥1
KEYNOTE 355

Median: 7,6 (IC 95%: 6,6-8,0) vs 5,6 (IC 95%: 5,4-7,4)
HR 0,74 (IC 95%: 0,61–0,90)
p= 0,0014
Pembrolizumab+Chemoterapy
vs
Placebo+ Chemoterapy

Progression-free survival (PFS)

Bucher method

HR 0,85 (1,16- 0,63)
p>0,05
No significant differences

ATEZOLIZUMAB
CPS≥1
IMPASSION130

Median: 7,5 (IC 95%: 6,7- 9,2) vs 5,3 (IC 95%: 3,8-5,6)
HR 0,63 (IC 95%: 0,50 – 0,80)
p=0,0025
Atezolizumab + nab-paclitaxel
vs
Placebo + nab-paclitaxel

Delta value according to ESMO guidelines **0,65**



Shakespeare's calculator which states that there is a **4.25%** probability that the value is below 0.65
Since this is a probability **of less than 17%,** we can conclude that these are **equivalent therapeutic alternatives.**

CONCLUSIONS

Pembrolizumab and atezolizumab could be considered ATE, however, recent studies such as the Impassion 131 bring a great deal of uncertainty to this determination.

Number: **6ER-033**